Literature DB >> 26143580

Deconstructing innate immune signaling in myelodysplastic syndromes.

Madeline Niederkorn1,2, Molly Smith1,2, Laura Barreyro1, Melinda E Varney1, Katelyn Melgar1,3, Daniel T Starczynowski1,2.   

Abstract

Overexpression of immune-related genes is widely reported in myelodysplastic syndromes (MDSs), and chronic immune stimulation increases the risk for developing MDS. Aberrant innate immune activation, such as that caused by increased toll-like receptor (TLR) signaling, in MDS can contribute to systemic effects on hematopoiesis, in addition to cell-intrinsic defects on hematopoietic stem/progenitor cell (HSPC) function. This review will deconstruct aberrant function of TLR signaling mediators within MDS HSPCs that may contribute to cell-intrinsic consequences on hematopoiesis and disease pathogenesis. We will discuss the contribution of chronic TLR signaling to the pathogenesis of MDS based on evidence from patients and mouse genetic models.
Copyright © 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26143580      PMCID： PMC4635673          DOI： 10.1016/j.exphem.2015.05.016

Source DB:  PubMed          Journal:  Exp Hematol        ISSN： 0301-472X            Impact factor:   3.084


  143 in total

1.  TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy.

Authors:  Chong-Shan Shi; John H Kehrl
Journal:  Sci Signal       Date:  2010-05-25       Impact factor: 8.192

2.  An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4.

Authors:  Precious G Motshwene; Martin C Moncrieffe; J Günter Grossmann; Cheng Kao; Murali Ayaluru; Alan M Sandercock; Carol V Robinson; Eicke Latz; Nicholas J Gay
Journal:  J Biol Chem       Date:  2009-07-10       Impact factor: 5.157

3.  A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies.

Authors:  Nadine Hövelmeyer; Sonja Reissig; Nguyen Thi Xuan; Petra Adams-Quack; Dominika Lukas; Alexei Nikolaev; Dirk Schlüter; Ari Waisman
Journal:  Eur J Immunol       Date:  2011-02-10       Impact factor: 5.532

4.  Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair.

Authors:  R M Hofmann; C M Pickart
Journal:  Cell       Date:  1999-03-05       Impact factor: 41.582

5.  B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice.

Authors:  Yuanyuan Chu; J Christoph Vahl; Dilip Kumar; Klaus Heger; Arianna Bertossi; Edyta Wójtowicz; Valeria Soberon; Dominik Schenten; Brigitte Mack; Miriam Reutelshöfer; Rudi Beyaert; Kerstin Amann; Geert van Loo; Marc Schmidt-Supprian
Journal:  Blood       Date:  2010-11-18       Impact factor: 22.113

6.  Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation.

Authors:  Fuminori Tokunaga; Hiroshi Nishimasu; Ryuichiro Ishitani; Eiji Goto; Takuya Noguchi; Kazuhiro Mio; Kiyoko Kamei; Averil Ma; Kazuhiro Iwai; Osamu Nureki
Journal:  EMBO J       Date:  2012-08-28       Impact factor: 11.598

7.  TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.

Authors:  Keiichiro Honma; Shinobu Tsuzuki; Masao Nakagawa; Hiroyuki Tagawa; Shigeo Nakamura; Yasuo Morishima; Masao Seto
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

8.  RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.

Authors:  Robert C Smallridge; Ana-Maria Chindris; Yan W Asmann; John D Casler; Daniel J Serie; Honey V Reddi; Kendall W Cradic; Michael Rivera; Stefan K Grebe; Brian M Necela; Norman L Eberhardt; Jennifer M Carr; Bryan McIver; John A Copland; E Aubrey Thompson
Journal:  J Clin Endocrinol Metab       Date:  2013-12-02       Impact factor: 5.958

9.  The deubiquitinase activity of A20 is dispensable for NF-κB signaling.

Authors:  Arnab De; Teruki Dainichi; Chozha Vendan Rathinam; Sankar Ghosh
Journal:  EMBO Rep       Date:  2014-05-30       Impact factor: 8.807

10.  Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes.

Authors:  Sophie Dimicoli; Yue Wei; Carlos Bueso-Ramos; Hui Yang; Courtney Dinardo; Yu Jia; Hong Zheng; Zhihong Fang; Martin Nguyen; Sherry Pierce; Rui Chen; Hui Wang; Chenghua Wu; Guillermo Garcia-Manero
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240
View more
  15 in total

Review 1.  Stem and progenitor cell alterations in myelodysplastic syndromes.

Authors:  Aditi Shastri; Britta Will; Ulrich Steidl; Amit Verma
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

2.  Loss of Toll-like receptor 2 results in accelerated leukemogenesis in the NUP98-HOXD13 mouse model of MDS.

Authors:  Darlene A Monlish; Sima T Bhatt; Eric J Duncavage; Zev J Greenberg; John L Keller; Molly P Romine; Wei Yang; Peter D Aplan; Matthew J Walter; Laura G Schuettpelz
Journal:  Blood       Date:  2018-01-22       Impact factor: 22.113

Review 3.  Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.

Authors:  Kathryn S Ivy; P Brent Ferrell
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

Review 4.  Chronic immune response dysregulation in MDS pathogenesis.

Authors:  Laura Barreyro; Timothy M Chlon; Daniel T Starczynowski
Journal:  Blood       Date:  2018-08-13       Impact factor: 22.113

Review 5.  Epigenetic and Transcriptional Regulation of Innate Immunity in Cancer.

Authors:  Chuan Chen; Na Man; Fan Liu; Gloria Mas Martin; Hidehiro Itonaga; Jun Sun; Stephen D Nimer
Journal:  Cancer Res       Date:  2022-06-06       Impact factor: 13.312

Review 6.  The Role of Toll-Like Receptors in Hematopoietic Malignancies.

Authors:  Darlene A Monlish; Sima T Bhatt; Laura G Schuettpelz
Journal:  Front Immunol       Date:  2016-09-28       Impact factor: 7.561

Review 7.  Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells.

Authors:  Shayda Hemmati; Tamanna Haque; Kira Gritsman
Journal:  Front Oncol       Date:  2017-11-13       Impact factor: 6.244

Review 8.  Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes.

Authors:  Luana Chiquetto Paracatu; Laura G Schuettpelz
Journal:  Front Immunol       Date:  2020-06-17       Impact factor: 7.561

Review 9.  Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS.

Authors:  Jennifer J Trowbridge; Daniel T Starczynowski
Journal:  J Exp Med       Date:  2021-06-15       Impact factor: 17.579

10.  Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes.

Authors:  Thomas Cluzeau; Kathy L McGraw; Brittany Irvine; Erico Masala; Lionel Ades; Ashley A Basiorka; Jaroslaw Maciejewski; Patrick Auberger; Sheng Wei; Pierre Fenaux; Valeria Santini; Alan List
Journal:  Haematologica       Date:  2017-10-05       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.